Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;74(7):825-37.
doi: 10.1007/s40265-014-0218-4.

Apremilast: first global approval

Raewyn M Poole  1 , Anita D Ballantyne
Affiliations
Review

Apremilast: first global approval

Raewyn M Poole et al. Drugs. 2014 May.

Abstract

Apremilast (Otezla(®)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet's syndrome, atopic dermatitis, and rheumatoid arthritis. Apremilast is indicated for the treatment of active psoriatic arthritis in adults. Apremilast has received its first global approval for this indication in the USA. Regulatory submissions for approval in this indication are under review in Canada and Europe. Regulatory filings have also been submitted for apremilast in the treatment of plaque psoriasis in the USA and Europe. This article summarizes the milestones in the development of apremilast leading to its first approval for the treatment of psoriatic arthritis.

PubMed Disclaimer

References

    1. Br J Pharmacol. 2010 Feb;159(4):842-55 - PubMed
    1. BMC Med. 2013 Apr 04;11:96 - PubMed
    1. J Am Acad Dermatol. 2013 Feb;68(2):255-61 - PubMed
    1. J Am Acad Dermatol. 2009 Sep;61(3):451-85 - PubMed
    1. Low Urin Tract Symptoms. 2012 Sep;4(3):140-3 - PubMed

MeSH terms

Substances